Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

Copd Clinical Trial

— OSCIVARI  

Official title:

Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04087590
• Other study ID #: 2018_24
• Secondary ID: 2018-003061-33
• Status: Recruiting
• Phase: Phase 2
• Start date: January 14, 2020
• Est. completion date: February 2023

Study information

• Verified date: August 2022
• Source: University Hospital, Lille
• Contact: Thierry PEREZ, MD,PhD
• Phone: 320445619
• Email: thierry.perez[@]chru-lille.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, single-arm, open label, multicentre, phase II pilot study to evaluate the immediate and short term (one month) impact of a new long acting double bronchodilator on innovative parameters in stable and moderate to severe COPD patients.

• Variability and complexity of resting tidal breathing

• Oscillatory resistance and reactance of airways Tidal volume variability and complexity is decreased in airway obstruction and is expected to improve with a bronchodilator treatment, together with lung mechanics.

The relationship with changes in dyspnea and conventional pulmonary function tests is the second aim of study.

After baseline assessment of these parameters, clinical and lung function evaluation will be performed 2 hours post-drug (peak drug effects). Patients will continue treatment with PT003 for 4 weeks. On Day 30, the same clinical and lung function assessments will be performed pre (trough) and 2h-post dose in order to obtain after-treatment measurements.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 35
• Est. completion date: February 2023
• Est. primary completion date: February 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female or male subjects aged 40-75 years Documented COPD in stable condition FEV1 between 30 % and 70 % predicted (post bronchodilator) Significant dyspnea with a mMRC dyspnea scale

Exclusion Criteria:

• History or current diagnosis of asthma or ACO (asthma-COPD overlap syndrome)

• Respiratory infection or COPD exacerbation within 6 weeks (2 months if it resulted in hospitalization) prior to screening

• Clinically significant or relevant cardiovascular conditions, laboratory tests, electrocardiogram (ECG) parameters

• Severe renal impairment eGFR < 30

• Narrow-angle glaucoma that, in the opinion of the Investigator, has not been adequately treated.

• Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that is clinically significant

Related Conditions & MeSH terms

• Copd
• Respiratory Aspiration

Intervention

Drug:
• Formoterol-glycopyrronium co suspension (PT003)
Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily

Locations

Country	Name	City	State
France	Hop Calmette Chu Lille	Lille

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Lille	AstraZeneca

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Analysis of tidal volume (VT) complexity (noise limit as main parameter )	Comparison of the noise limit between V2 baseline (pre-treatment) and V3 peak (2 hours +/- 30 min post dose).; Noise limit is a mathematical treatment of tidal breathing signal evaluating its complexity and no other description can be provided	at 1 month
Secondary	change of frequency-tidal volume pattern	the inspiratory time (Ti, measured in second) , the expiratory time (Te,measured in second) and the respiratory frequency	Baseline, at 1 month
Secondary	Tidal volume Largest Lyapunov component (an indicator of the sensitivity of the system to initial conditions)		Baseline, at 1 month
Secondary	change of resistance at 5Hz , at 20 Hz	The fundamental principle of forced oscillometry is that lung function can be assessed by measuring changes in pressure and flow in response to external pressure applied at the airway opening. Resistance is complex measure that incorporates the lack of changes in pressure and volume and the rate of these changes in response to pressure oscillations at a specific frequency.; All these measurements are expressed in the same unit (for resistance and reactance) and refer to oscillatory mechanics obtained by the same device. AX and resonant frequency are correlated to reactance.	Baseline, at 1 month
Secondary	Change of reactance	the fundamental principle of forced oscillometry is that lung function can be assessed by measuring changes in pressure and flow in response to external pressure applied at the airway opening. Reactance is complex measure that incorporates the changes in pressure and volume and the rate of these changes in response to pressure oscillations at a specific frequency at 5Hz was used. Reactance is thought to reflect the elastic properties of the lung.; All these measurements are expressed in the same unit (for resistance and reactance) and refer to oscillatory mechanics obtained by the same device.	Baseline, at 1 month
Secondary	Change of AX and resonant frequency	Area under reactance curve (AX) and resonant frequency are correlated to reactance.	Baseline, at 1 month
Secondary	change of spirometry parameters	Spirometry : FEV1, FVC, FEV1/FVC	at 1 month
Secondary	change in lung function as assessed through body plethysmography	Change from baseline to end of treatment in the following measures Total lung capacity (TLC) Residual volume (RV) Inspiratory capacity (IC) Functional residual capacity (FRC) All plethysmographic parameters shown here are lung volumes, expressed in liters, and are somewhat interrelated. For instance IC is TLC- FRC.There is no reason to separate these outcome measures	Baseline, at 1 month
Secondary	change of airway resistance (RAW) and specific airway conductance (sGAW).	sGaw is specific conductance, ie 1/resistance divided by the volume at which resistance was measured. These two parameters are always measured and used together.; All plethysmographic parameters shown here are lung volumes, expressed in liters, and are somewhat interrelated.	Baseline, at 1 month
Secondary	Visual Analogic Scale	Two VAS (± 100 mm ) will be used to evaluate changes (much worse-unchanged-much better) in dyspnea and chest tightness 2 hours after PT003 administration and at 4 weeks in through and post dose conditions	Baseline, at 1 month
Secondary	Likert scales	Likert scales (7 points) will assess changes in dyspnea and global health at visit 3 in comparison with pre treatment condition (V2).	Baseline, at 1 month
Secondary	BDI/TDI	The BDI/TDI is an instrument developed to provide a multidimensional measure of dyspnea in relation to activities of daily living. The Baseline Dyspnea Index (BDI) provides a measure of dyspnea at a single state, the baseline, and the Transitional Dyspnea Index (TDI) evaluates changes in dyspnea from the baseline state. The instrument consists of three components: functional impairment, magnitude of task, and magnitude of effort. For the BDI, each of these three components are rated in five grades from 0 (severe) to 4 (unimpaired), and are summed to form a baseline total score from 0 to 12. For the TDI, changes in dyspnea are rated for each component by seven grades from -3 (major deterioration) to +3 (major improvement), and are added to form a total TDI score from -9 to +9. Positive scores indicate an improvement, and a change from the BDI or a difference between treatments of 1 point has been estimated to constitute the minimum clinically important difference (MC	Baseline, at 1 month
Secondary	mMRC dyspnea scale	The Modified Medical Research Council (mMRC) dyspnea scale uses a simple grading system to assess a subject's level of dyspnea that consists of five statements about perceived breathlessness. It is an interviewer-administered ordinal scale on which subjects provide their dyspnea according to five grades of increasing severity (scores ranges from 0 (none) to 4 (very severe).	Baseline, at 1 month
Secondary	Modified Dyspnea Profile (MDP)	The MDP consists of 11 items evaluating both the sensory and affective dimensions of dyspnoea. One item (A1) assesses the unpleasantness of dyspnoea on a 0-10 visual numerical scale anchored by "neutral" (0) and "unbearable" (10). Five items assess the sensory dimension of dyspnoea, both in terms of quality and intensity (on a scale of 0-10). Five items assess the affective dimension of dyspnoea, also in terms of quality and intensity (on a scale of 0-10).	Baseline, at 1 month